AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application. With the amendments, claims 45-50, 52, 55, 58-59, 61-62, 64-67, 69-71, and 73-83 remain pending.

Listing of Claims:

1-44. (Canceled)

45. (Currently Amended) A method for treating ~~and/or preventing~~ a disease, disorder and/or condition of the respiratory system due to expression of a gene regulated by NF-KB, comprising the step of:

a) ~~administration of~~ administering a composition in the form of a dry powder, the composition comprising a double-stranded oligonucleotide in a naked form and one or more excipients, which are acceptable as pharmaceutical additives for a dry powder, directly to the respiratory system of a subject, wherein said double-stranded oligonucleotide consists of an oligonucleotide having a sequence selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 3 and an oligonucleotide complementary thereto.~~an NF-KB decoy and a pharmaceutically acceptable carrier to the respiratory system of a subject~~.

46. (Currently Amended) The ~~A~~ method according to claim 45, wherein said disease, disorder and/or condition of the respiratory system is an airway inflammatory disease, an airway stenosis or a nasal cavity inflammatory disease.

47. (Currently Amended) The ~~A~~ method according to claim 45, wherein said disease, disorder and/or condition of the respiratory system is COPD, asthma or rhinitis.

48. (Currently Amended) ~~A~~The method according to claim 45, wherein said direct administration to the respiratory system comprises administration into the airway, or the lung, or comprises transairway absorption or nasal absorption.

49. (Currently Amended) ~~A~~ The method according to claim 45, wherein said direct administration to the respiratory system is administration to the airway by atomization or inspiration.

50. (Currently Amended) ~~A~~ The method according to claim 45, wherein said direct administration to the respiratory system is achieved by means selected from the group consisting of a ~~Into the airway comprises administration by metered dose inhaler (MDI),~~ dry powder inhaler ~~Inhaler~~ (DPI), a nasal drop, a spray, a ~~or~~ nebulizer, a respirator and powder administration.~~,~~

51. (Canceled)

52. (Currently Amended) A method for treating ~~and/or preventing~~ a disease, disorder and/or condition of the respiratory system due to an eosinophil abnormality, comprising the step of:

a) ~~administration of~~administering a composition in the form of a dry powder, the composition comprising a double-stranded oligonucleotide in a naked form and one or more excipients, which are acceptable as pharmaceutical additives for a dry powder, directly to the respiratory system of a subject, wherein said double-stranded oligonucleotide consists of an oligonucleotide having a sequence selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 3 and an oligonucleotide complementary thereto.~~an NF-kB decoy and a pharmaceutical acceptable carrier to the respiratory system of a subject.~~

53-54. (Canceled)

55. (Currently Amended) ~~A~~The method according to claim 45, wherein said oligonucleotide is an oligonucleotide containing one or more thiophophatediester bonds or an oligonucleotide whose phosphatediester bond is substituted with a methylphosphate group~~NP-kB decoy is a NP-kB decoy or a derivative, variant or fragment thereof, and the derivative, variant or fragment has a biological activity~~.

56-57. (Canceled)

58. (Currently Amended) ~~A~~The method according to claim 45, wherein said excipient is ~~pharmaceutically acceptable carrier is at least one type~~ selected from the group consisting of ~~a liposome,~~ lactose and light anhydrous silicic acid.~~, trehalose, sucrose, mannitol and xylitol.~~

59. (Currently Amended) ~~A~~The method according to claim 52, wherein said oligonucleotide is an oligonucleotide containing one or more thiophophatediester bonds or an oligonucleotide whose phosphatediester bond is substituted with a methylphosphate group~~NF-kB decoy is a NP-kb decoy or a derivative, variant or fragment thereof, and the derivative, variant or fragment has a biological activity.~~

60. (Canceled)

61. (Currently Amended) ~~A~~The method according to claim 52 wherein said disease, disorder and/or condition of the respiratory system is an airway inflammatory disease, an airway stenosis or a nasal cavity inflammatory disease.

62. (Currently Amended) ~~A~~The method according to claim 52, wherein said disease, disorder and/or condition of the respiratory system is~~Is~~ COPD, asthma or rhinitis.

63. (Canceled)

64. (Currently Amended) ~~A~~The method according to claim 52, wherein said excipient is ~~pharmaceutically acceptable carrier is at least one type~~ selected from the group consisting of ~~a liposome,~~ lactose and light anhydrous silicic acid~~, trehalose, sucrose, mannitol and xylitol~~.

65. (Currently Amended) ~~A~~The method according to claim 52,

wherein said direct administration to the respiratory system comprises administration into the airway, or the lung, or comprises transairway absorption or nasal absorption.

66. (Currently Amended) ~~A~~The method according to claim 52, wherein said direct administration to the respiratory system is administration to the airway by atomization or inspiration.

67. (Currently Amended) ~~A~~The method according to claim 52, wherein said direct administration to the respiratory system is achieved by means selected from the group consisting of a~~into the airway comprises administration by metered dose inhaler (MDI),~~ dry powder inhaler (DPI), a nasal drop, a spray, a ~~or~~ nebulizer, a respirator and powder administration.

68. (Canceled)

69. (Currently Amended) ~~A~~The method according to claim ~~68~~45, wherein the dry powder has an aerodynamic average particle size of about 0.01 to about 50 micrometer.

70. (Currently Amended) ~~A~~The method according to claim ~~68~~69, wherein the dry powder has an aerodynamic average particle size of about 0.05 to about 30 micrometer.

71. (Currently Amended) ~~A~~The method according to claim ~~68~~70, wherein the dry powder has an aerodynamic average particle size of about 0.1 to

about 10 micrometer.

72. (Canceled)

73. (Currently Amended) ~~A~~The method according to claim ~~72~~52, wherein the dry powder has an aerodynamic average particle size of about 0.01 to about 50 micrometer.

74. (Currently Amended) ~~A~~The method according to claim ~~72~~73, wherein the dry powder has an aerodynamic average particle size of about 0.05 to about 30 micrometer.

75. (Currently Amended) ~~A~~The method according to claim ~~72~~74, wherein the dry powder has an aerodynamic average particle size of about 0.1 to about 10 micrometer.

76. (Currently Amended) ~~A~~The method according to claim 45, wherein a dosage of 10 mg to 100 mg per round of administration is provided.

77. (Currently Amended) ~~A~~The method according to claim 52, wherein a dosage of 10 mg to 100 mg per round of administration is provided.

78. (Currently Amended) ~~A~~The method according to claim 45, wherein the direct administration to the respiratory system comprises nasal absorption.

79. (Currently Amended) ~~A~~The method according to claim 78,

wherein said nasal absorption is by means ~~which is a formulation~~ selected from the group consisting of a nasal drop, a nasal spray agent, an agent for nebulizer, an agent for a respirator and a powder administration formulation.

80. (Currently Amended) ~~A~~The method according to claim 78, wherein said nasal absorption is by means~~which is~~ a nasal drop and said disease of the respiratory system is ~~for~~ rhinitis.

81. (Currently Amended) ~~A~~The method according to claim 52, wherein the direct administration to the respiratory system comprises nasal absorption.

82. (Currently Amended) ~~A~~The method according to claim 81, wherein said nasal absorption is by means~~which is a formulation~~ selected from the group consisting of a nasal drop, a nasal spray agent, an agent for nebulizer, an agent for a respirator and a powder administration formulation.

83. (Currently Amended) ~~A~~The method according to claim 81, wherein said nasal absorption is by ~~which Is~~ a nasal drop ~~for~~ and said disease of the respiratory system is rhinitis.

84-85. (Canceled)